Esperion Announces Agreement With Otsuka Pharmaceutical Co., Ltd. For Development And Commercialization Of NEXLETOL And NEXLIZET Tablets In Japan; Esperion To Receive $60M Up Front, Up To $510M In Milestones
Benzinga Newsdesk